Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
03 août 2020 09h25 HE
|
Cyclerion Therapeutics, Inc.
- IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively - - Completed $24 million equity private placement to accelerate clinical...
Cyclerion Therapeutics Completes $24 Million Private Placement
30 juil. 2020 09h00 HE
|
Cyclerion Therapeutics, Inc.
- Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease - - IW-6463 translational pharmacology and olinciguat STRONG Phase...
Cyclerion Updates Corporate Progress
10 avr. 2020 07h00 HE
|
Cyclerion Therapeutics, Inc.
– Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 – – Closed enrollment for IW-6463 translational pharmacology...
Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases
13 janv. 2020 07h00 HE
|
Cyclerion Therapeutics, Inc.
– Results in 110 subjects demonstrate favorable safety, CNS pharmacokinetics, and evidence of target engagement – – Study underway in elderly subjects to further assess cerebral blood flow and...
Cyclerion to Present at the J.P. Morgan Healthcare Conference
23 déc. 2019 07h00 HE
|
Cyclerion Therapeutics, Inc.
– Management to review the Company's sGC clinical pipeline programs: praliciguat for diabetic nephropathy, olinciguat for sickle cell disease, and IW-6463 for neurodegenerative diseases – CAMBRIDGE,...
Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference
27 nov. 2019 07h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy
30 oct. 2019 07h31 HE
|
Cyclerion Therapeutics, Inc.
– Study did not reach statistical significance on primary endpoint – – Positive trends on primary and secondary endpoints indicate profile that merits further investigation – – Company intends to...
Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)
30 oct. 2019 07h30 HE
|
Cyclerion Therapeutics, Inc.
– Study in HFpEF patients did not meet primary endpoint; company discontinuing development of praliciguat in HFpEF – – Conference call to be held at 8:30 a.m. ET today – CAMBRIDGE, Mass., Oct. ...
Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings
08 oct. 2019 08h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for...
Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17
10 sept. 2019 08h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...